|
Overall company Market Share Q2 2011 |
Overall company revenue, grew with moderate pace of 1.56 % slower than competitors within this segment.
<< More on CEPH Market Share.
|
|
| |
*Market share is calculated based on total revenue.
CEPH's vs. Competition, Data
(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)
| COMPANY NAME |
MARKET CAP
(in millions of $) |
REVENUES
(in millions of $) |
INCOME
(in millions of $) |
EMPLOYEES |
| Cephalon, Inc. |
CEPH |
0.00 |
0.00 |
0.00 |
- |
| Abbott Laboratories |
ABT |
194,097 |
45,548.00 |
8,554.00 |
107,000 |
| Bristol myers Squibb Company |
BMY |
161,736 |
47,144.00 |
6,636.00 |
30,250 |
| Eli Lilly And Company |
LLY |
293,081 |
29,070.70 |
5,691.60 |
33,625 |
| Johnson and Johnson |
JNJ |
451,489 |
95,588.00 |
18,366.00 |
132,200 |
| Merck and Co. Inc. |
MRK |
235,498 |
55,716.00 |
16,592.00 |
71,000 |
| Mylan N v |
MYL |
8,208 |
16,861.30 |
266.40 |
25,000 |
| Pfizer Inc |
PFE |
281,887 |
101,132.00 |
29,331.00 |
88,300 |
| Enact Holdings Inc. |
ACT |
4,325 |
-560.22 |
1,669.95 |
19,200 |
| Amgen Inc. |
AMGN |
134,561 |
32,341.00 |
6,576.00 |
24,300 |
| Celgene Corp |
CELG |
78,961 |
16,982.00 |
1,834.00 |
6,012 |
| Abbvie Inc. |
ABBV |
252,689 |
57,349.00 |
12,646.00 |
38,500 |
| SUBTOTAL |
2,096,532.59 |
497,171.78 |
108,162.95 |
575,387 |
|
